Kazia Therapeutics (KZIA) Debt Ratio (2018 - 2025)

Kazia Therapeutics (KZIA) posted Debt Ratio of 0.2 for Q4 2025, down 61.64% on a QoQ basis from 0.52 in Q2 2025, and up 77.01% year-over-year from 0.11 in Q4 2024.

Kazia Therapeutics (KZIA) Debt Ratio (2018 - 2025) Analysis & Trends

Kazia Therapeutics' Debt Ratio history runs 5 years deep, the most recent figure standing at 0.2 for Q4 2025.

  • Quarterly Debt Ratio rose 77.01% year-over-year to 0.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.2 (up 77.01% YoY) and the FY2025 annual result came in at 0.52, up 1669.97% from the prior year.
  • Debt Ratio was 0.2 for Q4 2025 at Kazia Therapeutics, down from 0.52 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.52 in Q2 2025 and bottomed at 0.05 in Q2 2022.
  • A 4-year average of 0.17 and a median of 0.11 in 2024 frame the typical range for Debt Ratio.
  • Annual changes were most pronounced in 2024 — Debt Ratio tumbled 68.06% — and 2025, when it soared 1669.97%.
  • Kazia Therapeutics' Debt Ratio stood at 0.05 in 2022, then soared by 752.28% to 0.35 in 2023, then tumbled by 68.06% to 0.11 in 2024, then soared by 77.01% to 0.2 in 2025.
  • Business Quant data shows KZIA's Debt Ratio at 0.2 in Q4 2025, 0.52 in Q2 2025, and 0.11 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Kazia Therapeutics 4.11 Mn 4.11 Mn - 0.20

Historic Data

Download Data
DateValue
Dec 31, 2025 0.20
Jun 30, 2025 0.52
Dec 31, 2024 0.11
Jun 30, 2024 0.03
Dec 31, 2023 0.35
Jun 30, 2023 0.06
Jun 30, 2022 -0.05
Jun 30, 2018 0.00